International Clinical Research Center, St. Anne’s University Hospital Brno
Research objectives:
Validation of the preparation of clinical grade GMP produced MSCs suitable for the treatment of neurodegenerative diseases will be set up- using molecular biology approaches, the hypothesis whether MSC1 polarization leading to increase an anti-inflammatory cytokines production also positively affects the production of CNTF and BDNF will be verified.
The aim is to design MSCs and validate culture protocol leading to the maximization of the therapeutic effect of these cells in AD. Motivation Thee ability of MSCs to secrete neurotrophic factors may improve the cellular milieu and limit cell loss in the setting of this complex AD pathophysiology. In addition, MSCs’ known immunomodulatory effects may limit the damage effects of activated glial cell related synaptic pruning and inflammation in general. MSCs also have the potential to deliver a healthy supply of mitochondria to the CNS thereby mitigating the impact of age and AD-related mitochondrial dysfunction.